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Peroxisome proliferator-activated receptors (PPARs) belong
to the nuclear hormone receptor family, which is deﬁned as
transcriptional factors that are activated by the binding of
ligands to their ligand-binding domains (LBDs). Although the
three PPAR subtypes display different tissue distribution
patterns and distinct pharmacological proﬁles, they all are
essentially related to fatty-acid and glucose metabolism. Since
the PPARs share similar three-dimensional structures within
the LBDs, synthetic ligands which simultaneously activate two
or all of the PPARs could be potent candidates in terms of
drugs for the treatment of abnormal metabolic homeostasis.
The structures of several PPAR LBDs were determined in
complex with synthetic ligands, derivatives of 3-(4-alkoxy-
phenyl)propanoic acid, which exhibit unique agonistic activ-
ities. The PPAR  and PPAR  LBDs were complexed with the
same pan agonist, TIPP-703, which activates all three PPARs
and their crystal structures were determined. The two LBD–
ligand complex structures revealed how the pan agonist is
adapted to the similar, but signiﬁcantly different, ligand-
binding pockets of the PPARs. The structures of the PPAR 
LBD in complex with an  / -selective ligand, TIPP-401, and
with a related  -speciﬁc ligand, TIPP-204, were also deter-
mined. The comparison between the two PPAR  complexes
revealed how each ligand exhibits either a ‘dual selective’ or
‘single speciﬁc’ binding mode.
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PDB References: PPAR 
LBD–TIPP-703, 2znn,
r2znnsf; PPAR  LBD–
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r2znpsf; PPAR  LBD–
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1. Introduction
The nuclear hormone receptor family of ligand-activated
transcription factors comprises 48 members in humans
(Chawta et al., 2001). The members of one subgroup, the
peroxisome proliferator-activated receptors (PPAR ,P P A R  
and PPAR / ), are the key transcriptional regulators in fatty-
acid and glucose metabolism (Rosen & Speigelman, 2001; Lee
et al., 2003). PPARs are activated by metabolites, such as fatty
acids, and synthetic ligands and they regulate gene expression
by binding to speciﬁc DNA response elements located in the
enhancer regions of target genes (Banner et al., 1993; Li et al.,
2003). Each PPAR subtype displays a distinct tissue distribu-
tion (Willson et al., 2000). PPAR  is expressed in tissues
involved in lipid oxidation, such as liver, heart, muscle and
kidney, and it regulates the genes associated with fatty-acid
uptake and metabolism. PPAR , which is expressed ubiqui-
tously, is associated with improved insulin sensitivity and
elevated HDL levels. PPAR  is expressed in adipose tissues,
macrophages and vascular smooth muscles and directs the
regulation of genes related to adipogenesis and lipid storage.
PPARs form heterodimers with the retinoid X receptor
(RXR) and ligand-bound PPARs adopt an activated confor-mation (Walczak & Tontonoz, 2002). Additional co-activator
proteins are recruited to create a complex, which coordinates
and regulates the expression of large gene arrays (Yu &
Reddy, 2007). Dysfunctional regulation of the expression of
these genes leads to a range of human diseases, including
atherosclerosis, cancer, diabetes and
obesity (Lehrke & Lazer, 2005).
Therefore, PPARs have attracted strong
interest from the pharmaceutical
industry.
Since the ﬁrst determination of the
crystal structure of the PPAR  LBD,
many atomic structures of PPAR LBDs
complexed with various ligands have
been reported (Nolte et al., 1998; Cronet
et al., 2001; Xu et al., 2002). Since PPAR
activation is substantially dependent
on ligand binding, most structural
studies have targeted the LBDs. Indeed,
synthetic ligands have made great con-
tributions to medicine. For example,
PPAR  agonists such as fenoﬁbrate are
clinically used for the treatment of
dyslipidaemia, while PPAR  agonists
such as pioglitazone are employed
for the treatment of type 2 diabetes
mellitus. Pharmacological approaches
generated the concept of ‘full’ and
‘partial’ agonists, in which the agonists
are grouped into classes depending on
their transcriptional activities. Several
crystal structures support such an idea:
the full agonists stabilize the C-terminal
helix H12 in the active conformation by
directly interacting with a key tyrosine
residue on the helix, while the partial
agonists interact with amino-acid resi-
dues on regions other than helix H12
(Gampeet al., 2000; Xu et al.,2001,2002;
Bruning et al., 2007). Structural studies
have also been oriented toward larger
components and complexes with co-
activator and corepressor peptides or
with the RXR LBD have been reported.
More recently, the intact full-length
structure of the PPAR –RXR 
heterodimer was reported and provided
clearer insights into the activation
mechanism of the receptor (Chandra et
al., 2008).
In contrast to synthetic ligands,
structural analyses with endogenous
ligands or metabolites, including pros-
taglandin, have been hampered, prob-
ably because of the insoluble nature of
hydrophobic fatty acids. However, a few
groups have surpassed this technical
barrier and determined the structures of the LBDs complexed
with several lipid metabolites, which have provided important
insights into PPAR  activation caused by naturally occurring
ligands (Itoh et al., 2008; Waku et al., 2009). These studies
revealed the interesting ﬁnding that receptor activation
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Figure 1
Crystal structures of PPAR LBD–TIPP complexes. (a) Chemical formulae of TIPP-703, TIPP-401
and TIPP-204. The numbers indicate theEC50 (nM), the molar concentration ofthe compounds that
affords 50% of the maximal reporter activity, in our PPAR-GAL4 chimeric reporter assays using
transiently transfected HEK-293 cells (Kasuga et al., 2006). Values in parentheses indicate the
activities of the antipodal (R) isomers of TIPP-703 and TIPP-401. For the structures of the four
complexes determined in this study, the columns in the table are coloured cyan (PPAR  LBD–
TIPP-703), green (PPAR  LBD–TIPP-703), orange (PPAR  LBD–TIPP-401) and magenta
(PPAR  LBD–TIPP-204). This colouring is used throughout the manuscript. (b) Overall structures
of the complexes. Proteins are represented as ribbon models and the ligands are depicted as space-
ﬁlling models, with F, C, N and O atoms in aqua, yellow, blue and red, respectively.requires covalent-bond formation between a cysteine residue
and the fatty acid and thus led to the proposal of an activation
mechanism that is distinct from that by synthetic ligands.
Although many studies have revealed the tissue-speciﬁc
distributions and distinct roles of the three PPAR subtypes,
these three subtypes are essentially related to gene-expression
regulation of proteins that are involved in fatty-acid metabo-
lism (Tenenbaum et al., 2005). If a single compound acts on
different PPARs simultaneously, it could exhibit novel phar-
macological effects and hopefully modiﬁed effects on patients
with symptoms of metabolic syndrome. This idea could be
possible even in terms of receptor conformations because the
LBDs of the three PPARs share signiﬁcant structural simi-
larity to each other; indeed, it has been reported that some
agonists can activate all three PPARs or two of the three
subtypes (Tenenbaum et al., 2005). For example, bezaﬁbrate is
an old and well known PPAR pan ( ,  ,  ) activator that was
the ﬁrst to be clinically tested. Recently, Artis et al. (2009)
developed a novel PPAR pan agonist, indeglitazar, using a
combination of biochemical and structural approaches.
Based on our long-standing structure–activity relation
(SAR) studies of nuclear receptors, we also succeeded in the
synthesis of agonist ligands, TIPP compounds, that have
unique functional characteristics with the PPARs, using a
series of 3-(4-alkoxyphenyl)propanoic acid derivatives as lead
compounds (Miyachi & Hashimoto, 2008). For example, TIPP-
204 speciﬁcally activates PPAR  (Kasuga et al., 2007; Kasuga,
Oyama, Nakagome et al., 2008) and TIPP0401 activates both
PPAR  and PPAR  (Kasuga et al., 2006), whereas TIPP-703
can activate all three PPARs (Kasuga, Yamasaki et al., 2008;
Fig. 1a). The high-resolution crystal structures of the PPARs
complexed with these ligands will not only provide the
structural basis for the speciﬁc or versatile binding mode of
these ligands, but also for the further development of drugs
that could be candidates for the treatment of altered meta-
bolic homeostasis. Here, we describe the crystal structures of
human PPAR LBD–TIPP ligand complexes determined at
2.0–3.0 A ˚ resolution. We obtained four of the six possible
LBD–ligand complexes between the three PPARs and the
three ligands. The PPAR  and PPAR  LBDs were both
solved in complexes with a pan agonist, TIPP-703. Although
the structure of the PPAR  LBD–TIPP-703 complex was not
determined in this study, we found a unique binding mode of
TIPP-703 to the two PPAR LBDs. TIPP-401 and TIPP-204
possess almost the same structure, except for minor parts.
Nonetheless, TIPP-204 can activate both PPAR  and PPAR ,
while TIPP-401 activates only PPAR . A detailed structural
comparison of the two complex structures bound to PPAR 
revealed the different binding modes between the PPAR / 
dual and PPAR -speciﬁc ligands.
2. Materials and methods
2.1. Protein expression and purification
The recombinant ligand-binding domains (LBDs) of human
PPAR  (residues 200–468), PPAR  (residues 195–476) and
PPAR  (residues 206–477) were expressed as N-terminal His-
tagged proteins using the pET28a vector (Novagen). Each
expression plasmid was transformed into Rosetta(DE3) pLysS
competent cells (Novagen) and the cells were grown in Terriﬁc
broth containing 100 mgm l
 1 kanamycin at 310 K to an OD600
of 0.6–0.8. Protein expression was induced with 1 mM iso-
propyl  -d-1-thiogalactopyranoside for 48 h at 289 K and the
cells were then harvested and frozen at 193 K until use.
For the puriﬁcation of the PPAR  LBD, the cells from a 1 l
culture were resuspended and disrupted in 25 ml buffer A
[20 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM TCEP,
10%(v/v) glycerol and a Complete protease-inhibitor cocktail
tablet (Roche)]. The soluble fraction was collected by centri-
fugation at 16 000 rev min
 1 and 277 K for 20 min. Poly-
ethyleneimine was added to the supernatant to a ﬁnal con-
centration of 0.15%(v/v) to remove nucleic acids derived from
the host cells. The soluble fraction was precipitated using 80%
saturated ammonium sulfate. The protein was resuspended in
the above sonication buffer and loaded onto a HisTrap HP
nickel-chelate column (GE Healthcare); the column was
developed with a linear gradient of 0–0.5 M imidazole. The
pooled fraction was dialyzed against buffer B (20 mM Tris–
HCl, 1 mM TCEP and 10% glycerol pH 8.0). Before dialysis,
25 units of thrombin protease were added to cleave the
N-terminal His tag. The solution was loaded onto a HiTrap Q
anion-exchange column (GE Healthcare), which was devel-
oped with a linear gradient of 0–1 M NaCl. The pooled frac-
tion was concentrated to about 5–10 ml and applied onto
a HiLoad 26/60 Superdex 75 gel-ﬁltration column (GE
Healthcare) equilibrated with buffer C (20 mM Tris–HCl,
150 mM NaCl, 1 mM TCEP and 10% glycerol pH 8.0).
In the case of the PPAR  LBD, the cell-lysis supernatant
was treated and partially puriﬁed as for the PPAR  LBD and
the protein was further puriﬁed by two steps of column
chromatography. After the addition of thrombin protease
(25 units) to cleave the N-terminal His tag, the pooled fraction
from the nickel-chelate column was dialyzed against buffer D
(20 mM MES, 10 mM DTT, 100 mM ammonium acetate pH
6.0) and loaded onto a HiTrap SP cation-exchange column
(GE Healthcare). The protein was eluted with a linear
gradient of 0.01–1.0 M ammonium acetate. Finally, the protein
was puriﬁed by gel-ﬁltration chromatography on a HiLoad
26/60 Superdex 75 column eluted with buffer E (20 mM
HEPES, 10 mM DTT, 500 mM ammonium acetate pH 7.5).
The PPAR  LBD was puriﬁed as described previously (Waku
et al., 2009).
2.2. Crystallization, data collection and model refinement
Crystals of the PPAR  LBD–TIPP-703 pan agonist com-
plex were obtained by cocrystallization. Firstly, 20 ml2 0m M
TIPP-703 in 100% DMSO was added to 2.5 ml PPAR  LBD
solution (approximately 1.2 mg ml
 1,4 5mM) and the mixture
was incubated for 2 h at 277 K. The complex was concentrated
to 7 mg ml
 1 using a 5000 molecular-weight cutoff Amicon
Ultra 4 centrifugal concentrator (Millipore) and was then
crystallized using hanging-drop vapour diffusion at 293 K; 1 ml
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volume of crystallization buffer consisting of 0.1 M HEPES
pH 7.5 and 25%(w/v) PEG 3350. Needle-shaped crystals were
obtained in a few days.
The two PPAR  LBD–ligand complexes were also obtained
by cocrystallization. The complexes were formed by diluting
protein solutions (0.1 mg ml
 1) containing higher concentra-
tions (about three times) of the ligand and the solutions were
concentrated to 6–7 mg ml
 1 prior to crystallization. The
PPAR  LBD–ligand complexes were crystallized by hanging-
drop vapour diffusion at 293 K with a reservoir solution con
taining 11–14%(w/v) PEG 4000, 200 mM KCl, 40 mM bis-tris
methane, 6%(v/v) 1,3-propanediol, 0.5%(w/v) n-heptyl- -d-
glucopyranoside, 1 mM EDTA and 1 mM CaCl2. Diffraction-
quality crystals which had a maximum dimension of 50 mm
grew within a few days from crystallization drops in which 2 ml
of the protein–ligand complex solution was mixed with 1 ml
crystallization buffer.
We have previously succeeded in determining the crystal
structures of several PPAR –ligand complexes with endo-
genous fatty acids and related compounds (Waku et al., 2009).
This study essentially involves the same strategy. We ﬁrst
crystallized the ligand-free PPAR  LBD by hanging-drop
vapour diffusion at 293 K using a
reservoir solution containing 0.1 M
HEPES pH 7.5 and 0.8 M sodium
citrate. The TIPP-703 agonist, at a con-
centration of 0.1 mM in reservoir solu-
tion containing 1% DMSO, was then
soaked into the unliganded crystals for
three weeks.
All crystals were ﬂash-cooled in a
liquid-nitrogen stream after brieﬂy
soaking them in a cryoprotection buffer
suitable for the PPAR LBD–ligand
complex. The crystallization reservoir
solution supplemented with 25%(v/v)
glycerol was used for cryoprotection of
the PPAR  LBD–ligand complex crys-
tals and that supplemented with 20%
PEG 1000 was used for the crystals of
the PPAR  LBD complexes. In the case
of the PPAR  LBD complex crystals, an
increase in the sodium citrate concen-
tration from 0.8 to 1.4 M and the further
addition of 30%(v/v) glycerol were
required for stable cryoprotection.
Diffraction data were collected on
BL38B1 at SPring-8 (Harima, Japan)
and were processed using HKL-2000
(Otwinowski & Minor, 1997). All
structures were solved by the mole-
cular-replacement method with the
program CNS (Bru ¨nger et al., 1998)
using the previously published struc-
tures as probes. The correctly posi-
tioned molecules werereﬁned with CNS
and O (Jones et al., 1991). Initial atomic models of the TIPP
compounds were built using MOE (Ryoka Systems Inc.) and
topology and parameter ﬁles for the reﬁnement were gener-
ated by the HIC-Up server (Kleywegt, 2007). The crystal-
lographic data and reﬁnement statistics are summarized in
Table 1.
3. Results and discussion
3.1. TIPP agonist ligands used in this study
The three TIPP agonists used in this study were developed
based on our SAR results. They share a common formula, with
a head part containing the carboxyl group, a central and a tail
benzene ring, with a linking group between the two benzene
rings (Fig. 1a). TIPP-703 (pan agonist), (S)-2-{3-[(4-adamantan-
1-ylbenzoylamino)methyl]-4-propoxybenzyl}butyric acid, has
a prominent adamantyl group at the para position of the tail
benzene ring and a propoxy group on the central benzene ring.
TIPP-401 ( /  dual agonist), (S)-2-{3-[(2-ﬂuoro-4-triﬂuoro-
methylbenzoylamino)methyl]-4-methoxybenzyl}butyric acid,
andTIPP-204( -speciﬁcagonist),(S)-2-{4-butoxy-3-[(2-ﬂuoro-
4-triﬂuoromethylbenzoylamino)methyl]benzyl}butyric acid,
research papers
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Table 1
Crystallographic data and reﬁnement statistics.
Values in parentheses are for the last shell.
PPAR –TIPP-703 PPAR –TIPP-703 PPAR –TIPP-401 PPAR –TIPP-204
Pan agonist Pan agonist  ,  dual  -speciﬁc
Data collection
Space group P21 C2 P21 P21
Unit-cell parameters
a (A ˚ ) 44.372 93.307 39.492 39.172
b (A ˚ ) 61.529 61.604 93.149 91.947
c (A ˚ ) 53.124 118.973 96.370 96.361
  ( ) 106.290 103.640 97.480 98.010
Wavelength (A ˚ ) 1.00000 1.00000 1.00000 1.00000
Resolution (A ˚ ) 35.0–2.00
(2.07–2.00)
50.0–2.40
(2.49–2.40)
50.0–3.00
(3.11–3.00)
50.0–2.65
(2.74–2.65)
No. of unique reﬂections 18142 (1646) 25166 (2065) 13670 (1178) 19488 (1827)
Completeness (%) 98.7 (90.8) 97.1 (80.3) 97.8 (84.9) 99.0 (93.3)
I/ (I) 10.6 (3.3) 15.3 (2.7) 7.7 (2.1) 8.6 (2.7)
Redundancy 3.7 (3.1) 3.5 (2.8) 3.7 (2.9) 3.7 (3.1)
Rmerge† (%) 6.4 (22.2) 4.1 (26.1) 8.8 (29.7) 9.3 (28.2)
Reﬁnement
Resolution range (A ˚ ) 35.0–2.00 50.0–2.40 38.0–3.00 42.4–2.65
Rwork‡/Rfree§ 21.4/25.3 24.0/28.6 23.0/28.8 21.4/27.6
No. of atoms
Protein 2054 4111 4198 4215
Water 146 46 5 83
Ligand 37 66 113 98
Average B factor (A ˚ 2)
Protein 24.74 49.32 42.46 31.73
Water 29.68 41.22 43.66 30.02
Ligand 28.45 65.85 25.22 31.76
R.m.s.d.
Bond lengths (A ˚ ) 0.008 0.010 0.010 0.008
Angles ( ) 1.2 1.3 1.4 1.3
PDB code 2znn 2zno 2znp 2znq
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where hI(hkl)i is the mean I(hkl) over symmetry-equivalent
reﬂections. ‡ Rwork =
P
hkl jFobsj j Fcalcj=
P
hkl jFobsj, where Fobs and Fcalc are the observed and calculated structure
factors, respectively. § Rfree was calculated using 5% of the total reﬂections, which were chosen randomly and omitted
from the reﬁnement.research papers
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Figure 2
Close-up views of the ligand-binding pockets. (a)P P A R   LBD–TIPP-703. (b)P P A R   LBD–TIPP-703. (c)P P A R   LBD–TIPP-401. (d)P P A R   LBD–
TIPP-204. The left column shows the OMIT Fo   Fc electron-density maps (contoured at 2.2 ) and the right columns show stereoviews of the interaction
between the ligand-binding pockets and the bound ligands. The amino-acid residues contacting the ligands are labelled.have a triﬂuoromethyl (CF3) group at the para position of the
tail benzene instead of the adamantane in TIPP-703 and an
additional ﬂuorine at the ortho position. The only difference
between TIPP-401 and TIPP-204 is the length of the carbon
chain on the central benzene ring. TIPP-401 has a methyl
group, while TIPP-204 has an n-butoxy chain. Considering the
TIPP ligand-activation ability, there are six possible complexes
between the three PPAR subtypes and the three TIPP ligands.
We tried to crystallize all of the PPAR LBD complex crystals
and consequently obtained and determined four types of
complex crystals. Based on a detailed comparison of these four
complexes, we were able to ascertain the adaptability and
selectivity of each TIPP ligand.
3.2. Crystallization and structure determination
We performed high-throughput crystallization screening
using a Mosquito automated nanodrop dispenser (TTP
Labtech). Typically, a 200 nl aliquot of the protein–ligand
complex solution was mixed with an equal volume of reservoir
solution from commercially available screening kits. We
generated duplicate plates for each screening kit and placed
one in a room-temperature (293 K) incubator and the other in
a cold (277 K) incubator.
Crystals of the PPAR  LBD–TIPP-703 complex that
diffracted to high resolution were obtained using this
screening strategy. The complexes crystallized under more
than ten conditions of the 1728 in the semi-automatic setup,
indicating that this complex has sufﬁcient structural stability to
be subjected to structure analysis (data not shown). Under
these conditions, we reproducibly obtained diffraction-quality
crystals using the hanging-drop vapour-diffusion method in
the traditional manual setup, in which 1 ml complex solution
was mixed with an equal volume of reservoir solution and
equilibrated against 500 ml reservoir solution. Although
several crystal structures of PPAR –ligand complexes have
been published, the present PPAR –TIPP-703 complex was
crystallized as a novel crystal form. In contrast, the present
screening did not allow us to produce any novel crystal forms
of the PPAR  LBD–ligand and PPAR  LBD–ligand com-
plexes that were suitable for structure analysis. They were
successfully crystallized under the previously reported condi-
tions and therefore straightforward structure determinations
were possible (Waku et al., 2009; Fytte et al., 2006).
The three crystals of the PPAR  and PPAR  LBD–ligand
complexes were obtained by cocrystallization and the bound
ligands within the binding pockets were clearly observed in
the electron-density maps. Thus, we could efﬁciently build the
atomic models of the ligands and achieved rapid convergence.
On the other hand, as for the PPAR  LBD–TIPP-703 com-
plex, we had to collect several sets of X-ray diffraction data in
order to determine the structure of the bound pan agonist
unambiguously. To obtain the high-quality crystal structure of
the PPAR  LBD–TIPP-703 complex, a three-week soaking of
the ligand into the crystal was required. Even in the best
structures determined at 2.4 A ˚ resolution, the propoxy group
located at the centre of TIPP-703 in the PPAR  LBD complex
was disordered. Nonetheless, the quality of the complex
structure is sufﬁcient to discuss the adaptability of this pan
agonist to the three PPARs.
3.3. Overview of the PPAR LDB–agonist ligand complexes
and comparisons with other PPAR LBD–ligand complexes
All of the PPAR LBDs fold into a three-layered sandwich
comprising mainly  -helices, as also observed in the nuclear
receptor LBDs. The PPAR  LBD–TIPP-703 crystal contained
one complex in the asymmetric unit, while the crystals of
PPAR  LBD–TIPP-703, PPAR  LBD–TIPP-401 and PPAR 
LBD–TIPP204 contained two molecules. In the two PPAR 
LBD structures, the protein–ligand interactions were essen-
tially the same in the two protomers in the asymmetric unit.
On the other hand, the two protomers in the asymmetric unit
of the PPAR  LBD–TIPP-703 complex exhibited slightly
different conformations at the C-terminus, leading to the loss
of several protein–ligand contacts (Waku et al., 2009). How-
ever, the overall interaction modes of the proteins with the
ligands were substantially conserved.
The ligand-binding sites of the PPAR LBDs generally
exhibit Y-shaped pockets. The deepest arm is located behind
helix 3, where the bound ligands contact both hydrophilic and
hydrophobic residues. In particular, the hydrophilic patch
contains the Tyr residue on the AF-2 helix (helix 12), which
plays a key role in interacting with the carboxyl group of the
ligands. The conformation of the AF-2 helix generally plays a
crucial role in the regulation of coactivator segment binding
(Nolte et al., 1998). The mostly hydrophilic second arm is
located on the opposite side to the ﬁrst arm, against helix 3.
The hydrophobic third arm also lies at the entrance to the
binding pocket.
The present four complexes generally show very similar
TIPP ligand-binding modes. The head carboxyl groups are
located in the ﬁrst cavity, making conventional interactions
with the polar side chains, and thus all of the PPAR LBDs
adopttheconventionalactiveconformationofhelix12(Fig.2).
The central benzene rings and the alkoxy groups are located in
the centre and the second cavity, respectively, and the tail
benzene and the additional groups lie at the entrance.
A database examination revealed that our PPAR LBD–
TIPP complex structures resemble those of PPAR  with AZ
242 (PDB code 1i7g; Cronet et al., 2001) and with a PPAR / 
dual agonist,  -acyl- -phenylpropanioic acid (PDB code 2npa;
Han et al., 2007), of PPAR  with rosiglitazone (PDB code
2prg; Nolte et al., 1998) and with a PPAR /  dual agonist, a
phenylpropanoic acid derivative (PDB code 2q8s; Casimiro-
Garcia et al., 2008), and of PPAR  with GW2331 (PDB code
1y0s; Takada et al., 2000) and with a 3,4,5-trisubstituted
isoxazole (PDB code 2j14; Epple et al., 2006) (see Supple-
mentary Fig. 2
1). Although the detailed binding modes of the
PPAR ligands differ depending on their chemical and phar-
macological characteristics, the carboxyl group head of the
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1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: MH5021). Services for accessing this material are described at the
back of the journal.ligands usually occupies a common position
with similar conformations. In fact, the local
similarity of the ligand-binding mode is even
apparent between our TIPP ligands and
natural fatty acids (Fytte et al., 2006; Itoh et
al., 2008; Waku et al., 2009).
3.4. Adaptability of the TIPP-703 pan
agonist
In our previous SAR study, the intro-
duction of an adamantyl residue at the para
position of the tail benzene ring drastically
improved the pan-agonism of the com-
pounds, particularly for PPAR  (Kasuga,
Yamasaki et al., 2008). Several adamantane-
containing compounds exhibited EC50
values, as estimated by our cell-based assay,
in the submicromolar range or lower. In
contrast, when the adamantyl moiety was
replaced by a triﬂuoromethyl group, the
EC50 values against PPAR  increased to a
micromolar or higher value. The present
structural analyses highlight the effect of the
adamantyl residue on the pan-agonism.
A close-up view of the superimposed
structures of the PPAR  and PPAR  LBDs
complexed with TIPP-703 is shown in
Fig. 3(a). The overall binding modes of the
pan agonist are similar between the two
PPARs, but signiﬁcant differences are
observed in the protein–ligand interaction.
In the PPAR  LBD–TIPP-703 complex, the
adamantyl group mainly contacts hydro-
phobic residues from the H20 helix (Ile241,
Leu247, Ala250 and Val255) and from the
 3 strand (Val332 and Ala333) at the
entrance of the ligand-binding pocket. In
contrast, in the PPAR  LBD complex the
same group mainly interacts with Arg280
and Ile281 on the H3 helix. Furthermore, in
the PPAR  LBD complex the propoxy
group of TIPP-703 in the second cavity of
the ligand-binding pocket is well ordered in
the crystal and interacts with the three
hydrophobic residues Met325, Met355 and
Phe359. In the PPAR  LBD complex, the
propoxy group of TIPP-703 should occupy a
similar position to that in the PPAR  LBD
complex. However, we did not observe any
signiﬁcant electron density corresponding to
the propoxy group of TIPP-703, although the ligand molecule
was mostly ordered in the crystal with an average B factor of
65.8 A ˚ 2. This indicates that the propoxy group interacts
weakly with PPAR  in the ligand-binding pocket. Interest-
ingly, the observed binding features are highly consistent with
our previous analyses: the length of the alkoxy group
(methoxy, ethoxy and propoxy) on the central benzene ring
did not drastically affect the afﬁnity towards PPAR , indi-
cating the lower contribution of the alkoxy group to the afﬁ-
nity of TIPP-703 towards PPARs.
The PPAR  LBD exhibits 80 and 65% identity to those of
PPAR  and PPAR , respectively, indicating that PPAR  is
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Figure 3
Comparison between the PPAR  LBD–TIPP-703 and the PPAR  LBD–TIPP-703 complexes.
(a) Stereoview of the superimposed structures. The PPAR  LBD–TIPP-703 complex is
coloured cyan and the PPAR  LBD–TIPP-703 complex is coloured green. The key contact
residues in the complexes are highlighted. Prominent interactions in each complex are
indicated by arrows. (b) Schematic view of the protein–ligand interactions. A structure-based
sequence alignment was generated around the ligand-binding pocket. In the PPAR  and
PPAR  sequences, the residues that interact with TIPP-703 are coloured blue (hydrophobic)
and red (hydrophilic).slightly more similar to PPAR  than to PPAR  (Fig. 3b and
Supplementary Fig. 1). Accordingly, TIPP-703 could bind to
PPAR  and PPAR  in a similar manner.
3.5. Selectivity between the a/d dual
agonist and the d-specific agonist
In contrast to TIPP-703, the dual
selectivity of TIPP-401 and the PPAR -
speciﬁc afﬁnity of TIPP-204 are attrib-
uted to the chain lengths of the alkoxy
groups at the centre of the ligand
molecules. In the structure of the
PPAR  LBD–TIPP401  /  dual agonist
complex, the methoxy group is oriented
toward the second small cavity but
makes fewer interactions with the
surrounding amino-acid residues
(Fig. 2c). When the methoxy group is
replaced by an n-butoxy chain, TIPP-
401 changes to the  -speciﬁc compound
TIPP-204, in which the extended alkoxy
group forms a hydrophobic interaction
with the Val334 side chain using the
distal methyl group (Fig. 2d). This
interaction indeed improved the acti-
vation of PPAR  (Fig. 1a).
On the other hand, the situation is
opposite in PPAR . In the second
binding cavity, the three amino acids of
PPAR , Val334, Leu339 and Ile364, are
replaced by larger amino acids, Met325,
Met330 and Met355, and thus a smaller
second binding cavity exists in PPAR 
than in PPAR  (Fig. 4). Therefore, the
methoxy group of TIPP-401 is suitable
for interaction with PPAR . When the methoxy group is
replaced by the longer n-butoxy group, TIPP-401 becomes
TIPP-204 and PPAR  Met325 and Met330 should be too close
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Figure 4
Comparison between the PPAR  LBD–TIPP-703 and the PPAR  LBD–TIPP-204 complexes. (a) Stereoview of the superimposed structures. The
PPAR  LBD–TIPP-703 complex is coloured cyan and the PPAR  LBD–TIPP-204 complex is coloured magenta. The key contact residues of the
complexes are highlighted. Prominent interactions in each complex are indicated by arrows. (b) Schematic view of the protein–ligand interactions,
highlighting the speciﬁcity of TIPP-204 toward PPAR .
Figure 5
Summary of the development of the present TIPP compounds from a PPAR -speciﬁc agonist, KCL.
The TIPP agonists used in this study were all developed from KCL using structure–activity relation
(SAR) studies. When speciﬁc chemical groups, coloured magenta, were introduced into the ligand
compounds, the transactivation abilities were drastically changed. The modiﬁcation effects of the
agonist ligands were found to increase the protein–ligand interactions at speciﬁc positions in the
ligand-binding pockets.and cause a steric clash with the n-butoxy group, even though
some conformational change could occur in both the PPAR 
Met325sidechainandthen-butoxygroupofTIPP-204(Fig.4).
Considering the results of our previous SAR study and the
current structural analyses, the distal single C atom could be
unfavourable for PPAR  (Kasuga et al., 2007; Fig. 1a). The
EC50 value of the transactivation activity of TIPP-401 against
PPAR  was 10 nM and that of another compound with an
n-propoxy group at the same position was 41 nM, still indi-
cating strong activity. This is also supported by the PPAR 
LBD–TIPP-703 pan agonist complex structure. TIPP-703 has
an n-propoxy group at the corresponding site and this group
lies in the second binding cavity with favourable contacts to
PPAR  (Fig. 2a). In contrast, the EC50 value of TIPP-204 with
an n-butoxy group for PPAR  was 250 nM, which is about 25
times higher than that of TIPP-401.
Our previous mutational analysis also supports the present
ﬁndings (Kasuga, Oyama, Nakagome et al., 2008). When the
three key residues (Val334, Leu339 and Ile364) of PPAR  that
form the interaction with TIPP-204 were replaced by Met
residues, the transactivation activities of the PPAR  mutants
by TIPP-204 were decreased. Conversely, when the three
methionines of PPAR  corresponding to the above hydro-
phobic residues were replaced by other residues (M325V,
M330L and M355I; Fig. 4), the activities of the mutants
induced by TIPP-204 were improved.
3.6. Development of the TIPP compounds from a
PPARa-specific ligand
The TIPP-401  /  dual agonist was developed from a
PPAR -speciﬁc agonist, KCL, by changing the linking group
between the central and tail benzene rings and by introducing
an Fatom at the 2-position of the tail benzene ring (Kasuga et
al., 2006). Owing to the introduction of the F atom in parti-
cular, TIPP-401 exhibited a more potent transactivation
activity against PPAR  than KCL: 170 and 12 nM, respec-
tively. As expected, the PPAR  LBD–TIPP-401 complex
structure exhibited a prominent interaction between the
protein and the ligand via the F atom (Fig. 2c). This F atom
makes van der Waals interactions with the geminal dimethyl
groups of the side chain of Leu339. The corresponding Met330
of PPAR  and Val339 of PPAR  do not interact with the
atoms on the tail benzene ring of TIPP-703 without the Fatom
(Figs. 2a and 2b), highlighting the effect of the F atom.
The present TIPP compounds have an ethyl group with an
(S)-conﬁguration at the  -position of the head carboxyl group
and all of the compounds exhibit more potent transactivation
activity than their antipodal (R) isomers (Kasuga et al., 2007).
Notably, the present structural study revealed the enantio-
selectivity of the TIPP compounds. The ethyl groups are
located at the deepest binding sites with the head carboxyl
groups and contact the surrounding hydrophobic residues.
When their R isomers approach the ligand-binding pocket, the
ethyl groups may cause a steric clash with the surrounding
residues, particularly those on the central parts of the H3
helix, even though some structural rearrangements could
occur in both the proteins and ligands.
In summary, the present crystal structures revealed our
successive logical design of the TIPP compounds from a
PPAR -speciﬁc ligand, KCL, at the atomic level. The history
of the development is summarized in Fig. 5. It is expected that
more effective ligands with unique characteristics could be
developed from the current X-ray crystallographic study. For
example, another PPAR pan agonist which exhibits more
potent transactivation activity than TIPP-703 has been
synthesized (Kasuga, Oyama, Hirakawa et al., 2008).
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